Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Health Canada

2 Strong Health Care Stocks to Add to Your Portfolio Now

The global healthcare industry is showing robust growth prospects with the growing adoption of advanced technologies, rising health awareness, and increasing chronic diseases. Amid rising spending on medicines, fundamentally strong healthcare stocks AbbVie (ABBV) and Bristol-Myers Squibb (BMY) might be ideal additions to your portfolio now. Read on.

StockNews.com

Canada is suffering a worrying shortage of children’s fever medication

‘Canadians should buy only what they need, so that other parents and caregivers can access medication so we can meet the needs of sick children,’ public health agency says

The Independent UK

Canada says imports of children’s fever medication will ease shortage

Health Canada says it secured a foreign supply of children’s acetaminophen that will be for sale ‘in the coming weeks’

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

First Take-Home Psychedelics Clinical Trial In North America Will Target PTSD

Vancouver-based psychedelics biopharma company Apex Labs Ltd.

Benzinga

Health Canada Grants Dealer's License To University Scientists For Magic Mushroom Cultivation

Ontario Agricultural College’s Department of Plant Agriculture University of Guelph (UG) professors and researchers Dr. Max Jones and Dr. Gale Bozzo received approval by the federal agency Health Canada to study psilocybin mushrooms.

Benzinga

Paying for plasma is the new normal: Why policy has changed decades after Canada’s tainted blood scandal

There has been a monumental policy shift in paying plasma donors in Canada.

The Conversation

Canada Update: Psychedelics Legal Landscape, Overview & Near-Term Predictions

Canada is hosting discussions on legal access to psychedelic-assisted therapies, especially after Alberta passed regulatory measures for this type of health s

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Marijuana Legalization In Kansas, MMJ Patients In Florida, UK Hemp Company & Ontario Lawsuit

Kansas Prepares MMJ Bill A special committee is preparing a medical cannabis legalization bill for the 2023 session.

Benzinga

Canada Studies Effects Of Psilocybin For COVID Frontline Healthcare Workers In Phase 2 Clinical Trial

Alberta-based ATMA Journey Centers Inc.

Benzinga

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Benzinga

Canadian advocates pledge to continue selling pure drugs amid overdose crisis

Over the last six years, the vast majority of overdose deaths in British Columbia have been driven by impurities in street drugs

The Guardian - US

Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics

Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog.

Benzinga

First International Psilocybin Supply Agreement For Optimi Health: Here Are The Details

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural psilocybin and other psychedelic substances, announced that it has entered into its first international psi

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Benzinga

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

Canada-Based Project Solace Aims To Provide Access And Data On Medical Psilocybin

TheraPsil, a Canadian coalition for psilocybin therapy legalization, together with the U.K. independent foundation Drug Science, has launched Project Solace.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Avant Brands Reports Record Recreational Cannabis Sales For Q2 2022 Of $3.1M

Avant Brands Inc. (OTCQX: AVTBF) (TSX:AVNT) (FRA:1BU0) released its financial results for the quarter ended May 31, 2022, revealing record recreational cannabis sales of $3.1 million, compared to $2.5 in previous quarter, an increase of $600,000 or 23%.

Birmingham Post

Gateshead's Shield Therapeutics awaits Canadian regulatory approval for iron deficiency drug

The pharmaceutical firm says Health Canada will screen its Accrufer lead product, with an outcome expected next year

Benzinga

Canada: 100+ Healthcare Professionals Protest Psilocybin Access Ban For Psychedelics-Assisted Therapy Training

A judicial review request was submitted to the federal court by more than 100 doctors, psychologists, clinical counselors, social workers and nurses across Canada challenging the country’s health minister’s decision to reject the professionals' application to use restricted psychoactive drugs for training in psilocybin-assisted therapy

The Conversation

$150M is not enough: Canada’s proposed Purdue Pharma settlement for opioid damages is paltry and won’t prevent future crises

On June 29, Canadian federal and provincial governments reached a proposed $150-million settlement with Purdue Pharma Canada, makers of OxyContin, an opioid-based pain medication. The settlement is intended to recover the health-care costs related to the damaging effects from the sale and marketing of OxyContin.

Benzinga

Psychedelics Company Nabs Health Canada Construction Permit, Find Out How They Got It

Canadian life sciences company Nirvana Life Sciences Inc. (CSE: NIRV), focused on research & development of non-addictive pain management and relapse prevention products for pain and addictions, has been granted approval to build its R&D facility in Vancouver by Canada’s governmental department of Health.

Benzinga

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

SIGA Technologies Announces $13M Worth Order For Its Monkeypox Treatment

SIGA Technologies Inc (NASDAQ:SIGA) has announced approximately $13 million in procurement orders for oral TPOXX (tecovirimat) The order includes $11 million for initial procaurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region with an established contract for oral TPOXX. "We expect a…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.